GCM
BLUE

Graham Capital Management’s bluebird bio BLUE Stock Holding History

Graham Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,091
Closed -$356K – 1115
2024
Q2 		$356K Sell
18,091
-183
-1% -$3.67K 0.01% 681
2024
Q1 		$468K Sell
18,274
-4,492
-20% -$115K 0.01% 644
2023
Q4 		$628K Buy
+22,766
New +$1.39M 0.01% 523
2023
Q3 		– Sell
-4,753
Closed -$313K – 1024
2023
Q2 		$313K Buy
+4,753
New +$348K 0.01% 668
2022
Q3 		– Sell
-39,096
Closed -$3.24M – 1072
2022
Q2 		$3.24M Buy
+39,096
New +$3.03M 0.13% 103

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Graham Capital Management's BLUE Position: Q3 2024 in Review

Graham Capital Management sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 18,091 shares — an estimated $356K sold.

Graham Capital Management first reported a position in BLUE in Q2 2022 and held it in 5 quarters. The position peaked at $3.24M in Q2 2022. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

  • Graham Capital Management reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 18,091 bluebird bio shares in Q3 2024, an estimated $356K.
  • Graham Capital Management first reported a position in bluebird bio in Q2 2022 and held it in 5 quarters.
  • Graham Capital Management's bluebird bio position peaked at $3.24M in Q2 2022.
  • 140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.